LAUSR

To evaluate the cost‐effectiveness of the post‐vaccination serologic testing (PVST) plus active‐passive immunoprophylaxis of infants born to hepatitis B surface antigen (HBsAg)‐positive mothers, a Markov model was constructed by R 4.0.1 to compare the current strategy (three‐dose HepB plus HBIG) and the PVST strategy (post‐vaccination serologic testing plus the current strategy) for infants of HBsAg‐positive mothers. Costs and utility scores were assessed from a field survey. Other model inputs were extracted from published literature and unpublished data from the Zhejiang provincial center for disease control and prevention (Zhejiang CDC). We calculated the incremental cost‐effectiveness ratio (ICER) as the main result within 1‐year cycle length with a 81 horizon among 50,000 infants and performed one‐way sensitivity analysis and probabilistic sensitivity analysis to explore the reliability of outcome. The ICER was −4130.18 yuan/quality‐adjusted life year (QALY) for the PVST strategy compared with the current strategy from the societal perspective. It was estimated that the PVST strategy would save about 3,809,546 yuan and prevent loss of 922.37 QALYs within 81 cycles among 50,000 infants. ICER was most sensitive to the discount rate, and the cost‐effectiveness acceptability curves showed that the PVST strategy reached a probability of being 100% cost‐effective below willing to pay (107,624 yuan). In conclusion, the PVST strategy had increased the utility and reduced cost among infants born to HBsAg‐positive mothers. The PVST strategy is a more cost‐effective choice for infants born to HBsAg‐positive mothers than the current strategy, and further promotion of the PVST project is recommended.